FDA approves pill that cuts COVID risk nearly 70%
The US has its first and only oral COVID-19 post-exposure prophylaxis (PEP) on its way, after a Phase III trial of the drug ensitrelvir met goals required for approval by the US Food and Drug Administration (FDA).Continue ReadingCategory: Infectious Diseases, Illnesses and conditions, Body and MindTags: FDA, Coronavirus (COVID-19), Drug development, Virus, Transmission
Original Source
Read the full article at Refractor →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.